Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF and aaPRP for Type 2 Diabetes
NCT05925829Phase 1Completed
- Sponsor
- Hayandra Peduli Foundation
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose stromal vascular fraction and platelet-rich plasma in type 2 diabetes mellitus (T2DM), sponsored by Hayandra Peduli Foundation. Primary endpoints: Change of baseline HbA1c level at 12 months and Safety of SVF and aaPRP at 12 months. Started Jan 2017; status: completed.
02
Drugs
autologous adipose stromal vascular fractionplatelet-rich plasma
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05925829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925829.